<body><div><img src="https://img.particlenews.com/image.php?type=thumbnail_580x000&amp;url=08ZUgp_0vLeAF7q00" alt="https://img.particlenews.com/image.php?url=08ZUgp_0vLeAF7q00" width="384" height="216" >Let’s discuss data of advanced treatment options for rheumatoid arthritis (RA) that may offer a faster pathway to achieving remission.<ul><li>Please discuss the SELECT-COMPARE trial head-to-head data on upadacitinib vs adalimumab. </li><li>Please discuss the use of upadacitinib for active RA refractory to biologic disease-modifying antirheumatic drugs (SELECT-BEYOND trial).</li><li>What are the remission rates seen with upadacitinib vs abatacept (SELECT-CHOICE trial)?</li></ul></div></body>

Block Source: hcplive.com

Misinformation

Clickbait

Old or repetitive news

Explicit content

Location not relevant

Let’s discuss data of advanced treatment options for rheumatoid arthritis (RA) that may offer a faster pathway to achieving remission. Please discuss the SELECT-COMPARE trial head-to-head data on upadacitinib vs adalimumab. Please discuss the use of upadacitinib for active RA refractory to biologic disease-modifying antirheumatic drugs (SELECT-BEYOND trial). What...

Advanced Treatment Options for RA: Exploring the Data

NewsBreak

Let’s discuss data of advanced treatment options for rheumatoid arthritis (RA) that may offer a faster pathway to achieving remission. Please discuss the S

Advanced Treatment Options for RA: Exploring the Data

Comments